<DOC>
	<DOCNO>NCT02706899</DOCNO>
	<brief_summary>This phase 1/2 study evaluate combination vadastuximab talirine ( SGN-CD33A ; 33A ) azacitidine subject previously untreated International Prognostic Scoring System ( IPSS ) Intermediate-2 high risk myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Study Vadastuximab Talirine ( SGN-CD33A ; 33A ) Combination With Azacitidine Patients With Previously Untreated Higher Risk MDS</brief_title>
	<detailed_description>In phase 1 portion study , escalate dos 33A evaluated combination azacitidine , dose 33A select proceed phase 2 . The phase 2 portion study randomize , double-blind placebo-controlled ; design compare overall response rate ( ORR ) 2 study arm .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Subjects cytologically/histologically confirm MDS accord World Health Organization ( WHO ) 2008 classification . Previously untreated Myelodysplastic Syndrome ( MDS ) Age ≥18 year age . Eligible therapy azacitidine . Life expectancy least 12 week . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Adequate baseline laboratory parameter . Received prior treatment MDS lenalidomide hypomethylating agent ( HMAs ) . History one follow myeloproliferative neoplasm : essential thrombocythemia , polycythemia vera , primary myelofibrosis . Second malignancy currently require active therapy ( except hormonal/antihormonal treatment , eg , prostate breast cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antibody-Drug Conjugate CD33 Antigen</keyword>
</DOC>